

**AMENDMENTS TO THE CLAIMS**

1-20. (Canceled)

21. (Currently amended) A method for enhancing a pre-existing immune response of inducing an antigen-specific cytotoxic T cell response comprising contacting administering an antibody, or binding fragment thereof, with a that binds to CD40 on human antigen presenting cell cells (APC) and contacting said human APC with a human T lymphocyte, wherein said antibody or binding fragment thereof binds to CD40 on said human APC without completely blocking binding of CD40L to CD40[[],] and wherein said the antibody is capable of enhancing inducing an APC-mediated ~~antigen-specific~~ human cytotoxic T lymphocyte response.

22. (Currently amended) The method of ~~claims~~ claim 21, wherein the antigen presenting cell is a monocyte derived dendritic cell.

23. (Currently amended) The method of ~~claims~~ claim 21, wherein the antibody is a monoclonal antibody or binding fragment thereof.

24. (Currently amended) The method of ~~claims~~ claim 21, wherein the monoclonal antibody is a chimeric, humanized, human, DEIMMUNISED<sup>TM</sup>, or a single chain antibody.

25-28. (Canceled)

29. (Previously presented)      The method of claim 21, further comprising administering IFN- $\gamma$ .

30. (Previously presented)      The method of claim 21, wherein the agonist anti-CD40 antibody is administered by injection.

**AMENDMENTS TO THE DRAWINGS**

The attached ten (10) sheet(s) of drawings include the required changes to Figures 1A-5B as set forth on form PTO-948 mailed September 3, 2002. These formal drawings do not include any substantive changes.

Attachment: Replacement sheets (10)